Literature DB >> 14871248

Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.

Giovanni Barosi1, Vittorio Rosti, Margherita Massa, Gian Luca Viarengo, Alessandro Pecci, Vittorio Necchi, Isabella Ramaioli, Rita Campanelli, Monia Marchetti, Mario Bazzan, Umberto Magrini.   

Abstract

Neoangiogenesis is an integral component of bone marrow myeloproliferation in patients with myelofibrosis with myeloid metaplasia (MMM). As extramedullary haematopoiesis is a constitutive feature of MMM, we studied spleen neoangiogenesis by a computerized image analysis in MMM patients. Compared with five normal subjects, spleen CD34-staining capillary vascular density (CVD) was 2.1-3.03 times higher than the upper range of normal in six of the 15 (40%) MMM patients. CD8-staining sinusoidal vascular density (SVD) was constantly normal or lesser than normal and was inversely correlated with CVD (R = -0.53; P = 0.04). In MMM patients who did not receive cytoreductive or radiation therapy in the month before splenectomy (n = 9), the CVD was a significant determinant of spleen size (R = 0.88; P = 0.04). In MMM patients, the number of spleen CD34+ haematopoietic stem cells was increased from 1.2 to 98 times the upper limit of normal, and predicted the expansion of CVD (R = 0.57; P = 0.03). A population of cells expressing the CD34+/CD133+/VEGFR-2+ angiopoietic phenotype was present in the blood and spleen of five of seven patients. These results document that neoangiogenesis is an integral component of spleen re-localization of haematopoietic stem cells and suggest a cellular mechanism for spleen neoangiogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871248     DOI: 10.1111/j.1365-2141.2004.04829.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

2.  The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis.

Authors:  Jiajing Qiu; Mohamed E Salama; Cing Siang Hu; Yan Li; Xiaoli Wang; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-05-22

3.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Authors:  Xiaoli Wang; Sonam Prakash; Min Lu; Joseph Tripodi; Fei Ye; Vesna Najfeld; Yan Li; Myron Schwartz; Rona Weinberg; Paul Roda; Attilio Orazi; Ronald Hoffman
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

4.  Genomic characterization of spleens in patients with myelofibrosis.

Authors:  Eran Zimran; Joseph Tripodi; Raajit Rampal; Franck Rappoport; Sharon Zirkiev; Ronald Hoffman; Vesna Najfeld
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

5.  Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

Authors:  Giovanni Barosi; Elisabetta Gattoni; Paola Guglielmelli; Rita Campanelli; Fabio Facchetti; Simona Fisogni; Judith Goldberg; Roberto Marchioli; Ronald Hoffman; Alessandro M Vannucchi
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

Review 6.  Rational therapeutic options for patients with myeloproliferative neoplasms.

Authors:  Ronald Hoffman
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

7.  C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.

Authors:  Xiaoli Wang; Sool Yeon Cho; Cing Siang Hu; Daniel Chen; John Roboz; Ronald Hoffman
Journal:  Exp Hematol       Date:  2014-11-08       Impact factor: 3.084

8.  A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.

Authors:  Xiaoli Wang; David Haylock; Cing Siang Hu; Wioleta Kowalczyk; Tianbo Jiang; Jiajing Qiu; Goar Mosoyan; Wu He; Netonia Marshall; John Mascarenhas; Anna Tarasova; Joshua Brody; David Winkler; Ronald Hoffman
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

9.  JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.

Authors:  Xiaoli Wang; Fei Ye; Joseph Tripodi; Cing Siang Hu; Jiajing Qiu; Vesna Najfeld; Jesse Novak; Yan Li; Raajit Rampal; Ronald Hoffman
Journal:  Blood       Date:  2014-09-05       Impact factor: 22.113

10.  Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.

Authors:  Xiaoli Wang; Cing Siang Hu; Bruce Petersen; Jiajing Qiu; Fei Ye; Jane Houldsworth; Kevin Eng; Fei Huang; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.